Nanobac Pharmaceuticals, Incorporated (NNBP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2007 | 4.12 Million USD | -23.2% |
| 2006 | 5.36 Million USD | 115.93% |
| 2005 | 2.48 Million USD | 869.24% |
| 2004 | 256.44 Thousand USD | -95.52% |
| 2003 | 5.73 Million USD | 0.0% |
| 2002 | - USD | 0.0% |
| 1999 | 4.69 Million USD | -26.42% |
| 1998 | 6.38 Million USD | 4.06% |
| 1997 | 6.13 Million USD | -2.21% |
| 1996 | 6.27 Million USD | 49.45% |
| 1995 | 4.2 Million USD | 31.25% |
| 1994 | 3.2 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2007 FY | 4.12 Million USD | -23.2% |
| 2007 Q1 | 3.31 Million USD | -38.32% |
| 2007 Q3 | 3.91 Million USD | 7.92% |
| 2007 Q2 | 3.62 Million USD | 9.6% |
| 2007 Q4 | 4.12 Million USD | 5.27% |
| 2006 Q4 | 5.36 Million USD | 14.82% |
| 2006 FY | 5.36 Million USD | 115.93% |
| 2006 Q1 | 3.69 Million USD | 48.52% |
| 2006 Q3 | 4.67 Million USD | 16.23% |
| 2006 Q2 | 4.02 Million USD | 8.94% |
| 2005 Q1 | 724.05 Thousand USD | 182.34% |
| 2005 FY | 2.48 Million USD | 869.24% |
| 2005 Q4 | 2.48 Million USD | 31.43% |
| 2005 Q3 | 1.89 Million USD | 24.36% |
| 2005 Q2 | 1.52 Million USD | 110.03% |
| 2004 Q1 | 6.67 Million USD | 16.56% |
| 2004 Q3 | 46.3 Thousand USD | -99.36% |
| 2004 Q4 | 256.44 Thousand USD | 453.88% |
| 2004 FY | 256.44 Thousand USD | -95.52% |
| 2004 Q2 | 7.24 Million USD | 8.53% |
| 2003 Q3 | 276.97 Thousand USD | -71.05% |
| 2003 FY | 5.73 Million USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q2 | 956.82 Thousand USD | 0.0% |
| 2003 Q4 | 5.73 Million USD | 1968.8% |
| 2002 FY | - USD | 0.0% |
| 2000 Q2 | 4.59 Million USD | -1.26% |
| 2000 Q1 | 4.65 Million USD | -1.0% |
| 1999 FY | 4.69 Million USD | -26.42% |
| 1999 Q3 | 4.73 Million USD | 0.0% |
| 1999 Q4 | 4.69 Million USD | -0.75% |
| 1998 FY | 6.38 Million USD | 4.06% |
| 1997 Q1 | 6.7 Million USD | 6.74% |
| 1997 FY | 6.13 Million USD | -2.21% |
| 1996 Q1 | 4.2 Million USD | 0.0% |
| 1996 FY | 6.27 Million USD | 49.45% |
| 1996 Q3 | 6.3 Million USD | 34.04% |
| 1996 Q2 | 4.7 Million USD | 11.9% |
| 1996 Q4 | 6.27 Million USD | -0.37% |
| 1995 Q2 | 3.1 Million USD | -3.13% |
| 1995 FY | 4.2 Million USD | 31.25% |
| 1995 Q1 | 3.2 Million USD | 0.0% |
| 1995 Q3 | 3.4 Million USD | 9.68% |
| 1995 Q4 | 4.2 Million USD | 23.53% |
| 1994 FY | 3.2 Million USD | 0.0% |
| 1994 Q3 | 1.9 Million USD | 0.0% |
| 1994 Q4 | 3.2 Million USD | 68.42% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 89.996% |
| SQZ Biotechnologies Company | 27.47 Million USD | 84.995% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 90.496% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 86.153% |
| Mesoblast Limited | 118.7 Million USD | 96.527% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -334.681% |
| Genus plc | 233.1 Million USD | 98.232% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -40.662% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -206.788% |
| Marizyme, Inc. | 18.71 Million USD | 77.978% |
| ContraFect Corporation | 2.88 Million USD | -43.074% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -449.594% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -2942.327% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -184.996% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -77.216% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 27.153% |
| MultiCell Technologies, Inc. | 202.58 USD | -2034630.477% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 92.83% |
| EV Biologics, Inc. | 1.49 Million USD | -175.762% |
| Q BioMed Inc. | 4.1 Million USD | -0.291% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 87.547% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -554.199% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -235.566% |
| Biomind Labs Inc. | 735.54 Thousand USD | -460.397% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 97.597% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 68.285% |
| Skye Bioscience, Inc. | 4.61 Million USD | 10.689% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -364.151% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -2812.673% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 29.792% |
| IMV Inc. | 28.88 Million USD | 85.729% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -15926.895% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -82.518% |
| GB Sciences, Inc. | 1.75 Million USD | -134.294% |
| Alpha Cognition Inc. | 1.22 Million USD | -237.762% |
| HST Global, Inc. | 98.31 Thousand USD | -4092.432% |
| CSL Limited | 12.18 Billion USD | 99.966% |
| Halberd Corporation | 150 Thousand USD | -2647.971% |
| Enzolytics Inc. | 996.33 Thousand USD | -313.711% |
| Resverlogix Corp. | 6.49 Million USD | 36.497% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -763.237% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1512.71% |
| argenx SE | 20 Million USD | 79.39% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 90.953% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -52.175% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -40212.538% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.013% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -1954.65% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -71.911% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1697.697% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 93.906% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -36.209% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1045.911% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 79.723% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -2672.853% |
| BioStem Technologies, Inc. | 4.71 Million USD | 12.511% |
| ONE Bio Corp. | 19.71 Million USD | 79.092% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1547.583% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1557.268% |
| Agentix Corp. | 50 Thousand USD | -8143.914% |
| LadRx Corporation | 33.6 Thousand USD | -12165.539% |
| Cell Source, Inc. | 9.25 Million USD | 55.458% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -445.085% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -445.085% |
| NovAccess Global Inc. | 2.19 Million USD | -87.372% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 41.721% |
| Itoco Inc. | 228.37 Thousand USD | -1704.891% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -1853.766% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 17.28% |
| Kadimastem Ltd | 891.22 Thousand USD | -362.504% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -925.748% |
| CytoDyn Inc. | 30.07 Million USD | 86.295% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -751.145% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -1071.52% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 47.289% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -3264.863% |
| Rebus Holdings, Inc. | 310 Thousand USD | -1229.664% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 12.952% |
| International Stem Cell Corporation | 4.17 Million USD | 1.341% |
| Bioxytran, Inc. | 1.92 Million USD | -114.128% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -6504.324% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -89.003% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 50.433% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 51.987% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -164.996% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -1438.044% |
| Neutra Corp. | 54.15 Thousand USD | -7511.266% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -125.244% |
| PureTech Health plc | 25.51 Million USD | 83.843% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -236.699% |
| IXICO plc | 472.02 Thousand USD | -773.253% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 73.408% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 93.38% |
| CSL Limited | 12.18 Billion USD | 99.966% |
| Cellectis S.A. | 92.77 Million USD | 95.557% |